72 results
Primary:To evaluate the clinical activity of GSK525762 in NUT Midline Carcinoma and other solid tumors.Secondary:Effect of treatment with GSK525762 on tumor growth and survival. Pharmacokinetics of GSK525762. Safety.
The objective of the study is to investigate whether trabectedin demonstrates sufficient antitumor activity against recurrent grade II or III to justify further investigation in phase III or as adjuvant therapy for newly diagnosed disease after…
Primary Objectives:*To explore whether early abiraterone exposure (AUC) is corre*lated to treatment response after 3 months and 6 months of therapy (primarily based on radiographic response (RECIST re*sponse: SD, PR, CR) and secondary on…
Primary: To evaluate the safety of GSK2849330 in a larger population of subjects in molecularly-defined tumor histology groups at the dose regimen(s) recommended for further exploration in Part 1. Secondary: Clinical benefit, pharmacodynamics,…
The overall objective of this phase I/II three-part study is to evaluate the benefit of 12 weeks once daily dosing with ASP9521 in a population of patients with metastatic castrate resistant prostate cancer (CRPC) who have failed one or more lines…
To assess the safety of a single dose of intravenous EC17 injection in patients with ovarian, lung, breast cancer and parathyroid adenomas. To assess concordance of fluorescent signal and tumor status of resected tissue, in the case of ovarian, lung…
Demonstrate an increase of 2-year overall survival (OS) of 15 % (from 50% to 65 %) vs historical controls of the addition of nitroglycerin to radiotherapy (±chemotherapy) of stage I-IV NSCLC.
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
Primary objective:• Phase Ib: to assess the feasibility and safety of the addition of cetuximab to methotrexate for recurrent or metastatic SCCHN • Phase II: to assess the efficacy of the addition of cetuximab to methotrexate for recurrent or…
The primary objective of this trial is to determine if EMD 1201081 (formerly known as IMO-2055) has anti-tumor activity in subjects by examining its effects on accepted clinical endpoints in combination with cetuximab. • To evaluate progression-free…
There will be three formal interim analyses during the study. Interim Analysis 1 will occur at the end of Phase II when approximately 162 PFS events (defined as disease progression or death due to any cause, whichever occurs first) have been…
Primary objective:To assess the puncture free survival after start of treatment with cediranib (time to first need for paracentesis or thoracentesis or time to death, which event occurred first)Secondary objectives:-To assess the palliative effects…
Non invasive imaging of hypoxia with the aid of PET-scans could help to select the patients having a hypoxic tumor who could be treated with specific anti-hypoxic treatments. The added value of additional anti-hypoxic treatments depends on the…
The primary objective of this study is to establish the sensitivity and specificity of an oral uracil loading test as a potential screening tool for DPD deficiency
To improve normalcy of food intake (food quantity and quality, decrease use of tube feeding/ nutritional supplements) in patients with head and neck cancer with pre-, per- and post treatment radiotherapy due to individually tailored swallowing…
To determine the test-retest variability of quantitative hypoxia imaging with FAZA-PET, both in untreated subjects (track A) and during radiotherapy (track B). The purpose of this study is to validate FAZA-PET as a selection criterion for…
The first objective is to assess which determinants predict swallowing dysfunction after curative (chemo)radiation. We want to determine the possible relationships between the radiation dose distributions in anatomical structures involved in…
The primary objective is to select one of two platinum strategies to be used in this regimen for use as experimental arm in Phase III. This is a screening feasibility study addressing purely investigational approaches.
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
The aim of the study is to investigate the feasibility, safety, toxicity, quality of life (QoL), and regional control of unilateral ENI using SNM with SPECT/CT to select patients with unilateral drainage in lateralized HNSCC treated with primary…